February 16, 2011 | Sanofi-Aventis has agreed to buy Cambridge-based Genzyme for $74 a share, valuing the biotech at $20.1 billion. In a statement, the pharma reportedly also agreed to make additional cash payments to Genzyme shareholders contingent on the success of several of the company's drugs. Forbes